Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cadonilimab in recurrent or metastatic vulvar and vaginal cancer
ChiCTR2400080316Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in Vulval carcinoma and vaginal cancer (2 cohorts), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Vulval carcinomavaginal cancer
Beyond the preview
Go deeper on ChiCTR2400080316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080316.